Previous 10 | Next 10 |
Gainers: Kiniksa Pharmaceuticals (NASDAQ:KNSA) +13%, Ocugen (NASDAQ:OCGN) +13%, Calliditas Therapeutics (NASDAQ:CALT) +11%, Context Therapeutics (NASDAQ:CNTX) +10%, Bone Biologics (OTCPK:BBLG) +7%. Losers: ABVC BioPharma (NASDAQ:ABVC) -32%, Semler ...
Clene (NASDAQ:CLNN) announces that the company's mid-stage trial of CNM-Au8 failed to meet the primary endpoint as a disease modifying treatment for people with early amyotrophic lateral sclerosis (ALS). Shares slide more than 30% premarket. RESCUE-ALS was a 36-week r...
RESCUE-ALS Phase 2 Trial did not meet primary MUNIX biomarker endpoint or secondary FVC endpoint at week 36; MUNIX efficacy signal was observed at week 12 (p=0.057) MUNIX trial results demonstrated protection of lower motor neurons in the pre-specified subset of li...
Gainers: Xenon Pharmaceuticals XENE +76%, Milestone Scientific (NYSE:MLSS) +15%, Clene (NASDAQ:CLNN) +12%, OpGen OPGN +11%, Adverum Biotechnologies ADVM +8%. Losers: Owlet (NYSE:OWLT) -25, REGENXBIO (NASDAQ:RGNX) -21%, Omeros (NASDAQ...
SALT LAKE CITY, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease usi...
SALT LAKE CITY, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease usi...
Final patient visit has been completed in its Phase 2 RESCUE-ALS study; study close-out activities have commenced 90% of eligible patients are continuing to be treated under a long-term open label extension Interim blinded efficacy data after 9-months of treatm...
SALT LAKE CITY, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease ...
Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8®, a gold nanocrystal suspension Phase 2, placebo-controlled RESCUE-ALS trial remains on track for top-line data in 2H 2021 Interim blinded RESCUE-AL...
SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease usin...
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...